Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis

Diamant Thaçi*, Dave Singh, Mark Lee, Helen Timmis, Dominique Jacobs, Paul Passier, Susanne Rohrer, Johan Beetens, De Phung, Eric Sondag, Goran Babic, Guido Würth, Pia Kloepfer, Stefan Härtle, Silke Hüttner

*Corresponding author for this work
2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science